VoxCell BioInnovation and adMare Partner to Validate Bioprinted Cancer Models for Antibody Therapy Development
Key Insights
VoxCell BioInnovation (search) and adMare BioInnovations (search) have formed a research partnership to validate a novel antibody-based immune-modulating therapy using bioprinted vascularized cancer tissue models.
The collaboration leverages VoxCell's human-relevant 3D bioprinted constructs that combine tumor, immune, and stromal compartments with perfused vasculature to better predict drug behavior.
This partnership aligns with FDA initiatives to reduce animal testing for monoclonal antibodies by expanding New Approach Methodologies for more predictive preclinical evaluation.
VoxCell BioInnovation (search) and adMare BioInnovations (search) have announced a research partnership to validate both the scientific and commercial viability of a novel antibody-based immune-modulating therapy using advanced bioprinted tissue models. The collaboration represents a significant step toward more human-relevant preclinical testing as the pharmaceutical industry moves away from traditional animal models.
Advanced Bioprinting Technology for Drug Development
VoxCell's platform creates human-relevant vascularized cancer tissue models by combining human tumor, immune and stromal compartments with a perfused, endothelial-lined vasculature in a single bioprinted construct. The models are specifically designed to support large biologics, immune-modulating therapies and other modalities where antibody transport, endothelial barrier function and immune complexity drive in vivo behavior.
"Our vascularized tissues bring perfusion, endothelial barriers, immune cells, and stroma into one human-relevant system," said Dr. Karolina Valente, CEO and Chief Scientific Officer of VoxCell. "Working with adMare on a novel biologic is exactly the use case the FDA had in mind when it called for more predictive, human-relevant tools."
The bioprinting process produces perfusable vascular networks inside human-like tissue, addressing what the companies describe as a long-standing gap in 3D cell culture technology. This approach enables quantitative readouts across efficacy and safety endpoints that legacy in vitro and in vivo models struggle to deliver.
Regulatory Alignment with FDA Initiatives
The partnership comes as the US Food and Drug Administration advances its plan to significantly reduce animal testing for monoclonal antibodies and other biologics. The agency is expanding the use of New Approach Methodologies (NAMs), including human-relevant 3D tissue platforms, organ-on-chip systems, and AI-based models, to improve preclinical translation rates.
"Animal models often miss the biology that determines whether a human drug works," Valente explained. The collaboration aims to demonstrate that bioprinted tissue models can provide better decisions earlier in the development process while reducing animal usage.
Strategic Company Building Approach
Matthew J. Carlyle, President and CEO of adMare BioInnovations (search), emphasized the strategic value of integrating advanced preclinical tools into the company creation process. "By integrating VoxCell's human-relevant vascularized tissue platform into our scientific and commercial validation process, we can generate stronger preclinical safety and efficacy evidence sooner," Carlyle said.
adMare's mission focuses on translating breakthrough scientific discoveries into investable Canadian life science companies and new therapies that reach patients. The partnership with VoxCell represents part of this broader strategy to de-risk innovation and create long-term value in the biotechnology sector.
Broader Impact on Immuno-Oncology Development
The data generated under this collaboration will serve dual purposes: informing adMare's specific program development while contributing to a broader effort to qualify VoxCell's vascularized cancer tissue model as a reference NAM for immuno-oncology biologics. This qualification process could establish new standards for preclinical testing in the field.
The collaboration applies perfusable, immune-competent 3D bioprinted cancer tissue models to preclinical evaluation of next-generation oncology biologics, supporting the FDA's push toward more predictive, human-relevant testing methodologies. The result is a human-like system that recapitulates antibody delivery, immune activity, and downstream tumor biology in ways that traditional models cannot achieve.